A study that defines the best medication for treating acute injuries with the Corona virus

In a study published in the patrol “The Lancet Respectory Medicine”, a group of medicine known as the “Janus kinaz” inhibitors, which work by delaying the immune system, should be the first rule to treat patients who enter hospitals due to the Corona virus. The researchers analyzed the individual results of approximately 13 thousand adults entering the hospitals due to the Corona virus, and participated in 16 random experiences compared to other drugs between May 2020 and March 2022. In general, 11.7% of patients who received Janus Kiniz -Inhibers received with the twenty -eight -day day compared to 13.2% of the other. Steroid, or medication that occurs the inflammatory protein signals IL-6. After calculating the individual risk factors, the possibility of death by the twentieth eighth day was 33% less in the group ‘Janus kiniz’ inhibitors. Corona -virus treatment, published with the study, said: “These results should be in addition to the guidelines of the World Health Organization regarding the treatment of the Corona virus, whether in the United States of America or Europe.” She added: “Although the pandemic is over, and the Corona virus no longer arises as in the past, the delay in the spread and adoption of treatment practices based on best evidence can be harmful.” Janeos Kiniz brakeers include the inhibitors of Zejan (Tawasitinib), produced by Payzer and Olomant (Parisitinib) of Eli Lily, as well as Renfuk (Opadacitinib) of APF. These inhibitors also reduced the need for modern artificial respirators, or other respiratory support devices, and allowed the hospital to leave about one day, as well as reducing serious negative complications. The results were identical, regardless of the case of vaccinating patients against the Corona virus.